Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 246

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 246
---
 M.B.A. from Harvard Business School.

Mr. Atwood was selected
to serve on our board of directors because of his experience in the biotechnology industry, his years of business and leadership experience
and his financial sophistication and expertise.

Michael Byrnes has
served as a member of our board of directors since February 2024. Mr. Byrnes has served as the Chief Financial Officer of eFFECTOR Therapeutics
since December 2020. Previously, Mr. Byrnes was Senior Vice President of Finance at Principia Biopharma, Inc. from January 2020 until
its acquisition by Sanofi in September 2020. Prior to that, Mr. Byrnes served as the Chief Financial Officer of Alkahest, Inc. from May
2018 to January 2020 and Chief Financial Officer of Ocera Therapeutics, Inc., from December 2014 until its acquisition by Mallinckrodt
Pharmaceuticals in December 2017. Mr. Byrnes served as Corporate Controller of Maxygen, Inc. from March 2010 to December 2014 and prior
to that, held finance positions of increasing responsibility from 2000 to 2010 with NeurogesX, Inc., Lipid Sciences, Inc. and ADAC Laboratories,
Inc., a Philips Medical Systems company. Mr. Byrnes received his B.S.C. in Finance from Santa Clara University and an M.B.A. from California
State University, Hayward.

Mr. Byrnes was selected
to serve on our board of directors based on his substantial leadership and management experience in the biopharmaceutical industry.

Kathleen LaPorte
has served as a member of our board of directors since February 2024, and previously served a member of PBAX’s board of directors
from October 2021 until the Closing of the Business Combination in February 2024. Ms. LaPorte is an experienced executive, founder and
board member, focused on life sciences. She co-founded New Leaf Ventures, served as a General Partner of The Sprout Group, and was Chief
Business Officer and Chief Executive Officer of Nodality Inc. Ms. LaPorte has served on sixteen public company boards and fourteen public
company audit committees and numerous private company boards. Ms. Laporte currently serves as an independent director for Bolt Biotherapeutics
(Nasdaq: BOLT), Precipio Diagnostics (Nasdaq: PRPO), 89Bio (